IPHA - Innate Pharma Short-Term Debt to Capital

Symbol and logo of brand Innate Pharma, S.A. (IPHA)

The following quotes for Innate Pharma S.A. (IPHA) on GURU.Markets show the 0.00 indicator. Innate Pharma S.A. (IPHA) operates in the immunotherapy oncology sector. The business faces fierce competition and concerns regarding final drug trials. The French research center minimizes disruptions by utilizing third-party bio-manufacturing plants. The firm is currently developing a new type of antibodies, leveraging collaborations with the market's largest players.

Current Liabilities to Capital: Innate Pharma, S.A. (IPHA) for 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for innate-pharma.com (IPHA)

- stock value and consensus price forecast:
Price Chart Innate Pharma, S.A.|IPHA - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Innate Pharma SA|IPHA - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Innate Pharma|IPHA - Total Stockholders' Equity|Market Value to Book Value Ratio innate-pharma.com|IPHA - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Innate Pharma S.A.|IPHA - Long-Term Liabilities to Capital|Short-Term Debt to Capital Innate Pharma|IPHA - Company Total Indebtedness|Debt to Book Value Innate Pharma SA|IPHA - Long-Term Debt|Company Current Liabilities Innate Pharma|Quick Ratio innate-pharma.com
- company profitability and valuation multiples indicators:
IPHA - Net Financial Result
Initial company analysis:Innate Pharma, S.A. IPHA
Signature product of innate-pharma.com

Investors assess fundamental risks through the analysis of liquidity and debt load. For Innate Pharma S.A. (IPHA), whose revenues depend on partner payments for antibody clinical trials, controlling current liabilities is critical. By analyzing the change in the ratio of short-term borrowed capital to equity, we determine the proportion of debt due within one year relative to equity. Low values confirm the financial stability of Innate Pharma S.A. (IPHA) during the period of awaiting test results.

Competitors of Innate Pharma S.A. (IPHA)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Pyxis Oncology - Short-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Current Liabilities to Capital|IOBT: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital STRO (sutrobio.com)|INKT: Short-Term Debt to Capital|HOWL - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Immix Biopharma Inc.|Short-Term Debt to Equity Ratio alxoncology.com (ALXO)|Short-Term Debt to Equity Cue Biopharma (CUE)|Short-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital MAIA Biotech MAIA|LIMN - Short-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Short-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity